SOME TISSUE MARKERS AND MULTIGENE SIGNATURES OF BREAST CANCER: PROGNOSIS AND DETERMINATION OF DRUG SENSITIVITY

DOI: https://doi.org/None

G.P. Guens Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Delegatskaya Str., 20, Moscow, Russian Federation, 127473

Prediction of clinical outcome of breast cancer (BC) is a multi-level process that includes the clinical and anatomical assessment both of the disease and the expression levels of proteins, DNA and RNA. This article discusses the application of traditional and new tissue prognostic markers in the clinical practice, as well as multigene signatures – Oncotype DX and MammaPrint. There are presented results of clinical studies on the use of chemotherapy, hormonal therapy, and targeted therapy, depending on the molecular biological subtypes of BC. In addition, there is represented the author’s own research on a new prognostic marker of BC – a multifunctional protein YB-1. High mRNA expression of YB-1 gene is associated with a worse disease-free survival in both univariate and multivariate analysis and allows to identify a group of patients who are at high risk of the disease progression. Also author describes the current state of research on the application of new markers – proteins uPA, PAI-1 and microRNA for disease prognosis
Keywords: 
breast cancer, multifunctional protein YB-1, multigene signatures, Oncotype DX, MammaPrint, uPA, PAI-1
Список литературы: 
  1. Mishra A., Verma M. Cancer biomarkers: are we ready for the prime time? Cancers. 2010; 2 (1): 190–208.
  2. Gianni L., Pienkowski T., Im Y.H. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13: 25–32.
  3. Luporsi E., André F., Spyratos F. et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res. Treat. 2012; 132 (3): 895–915.
  4. Sorlie T., Tibshirani R., Parker J. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA. 2003; 100 (14): 8418–23.
  5. Cardoso F., Piccart-Gebhart M., Van’t Veer L., Rutgers E; TRANSBIG Consortium. The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol. Oncol. 2007; 1: 246–51.
  6. Cardoso F., Van’t Veer L., Rutgers E. et al. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 2008; 26: 729–35.
  7. Sparano J.A. TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer. 2006; 7: 347–50.
  8. Harris L., Fritsche H., Mennel R. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007; 25 (33): 5287–312.
  9. Paik S., Shak S., Tang G. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004; 351 (27): 2817–26.
  10. van ‘t Veer L.J., Dai H., van de Vijver M.J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415 (6871): 530–6.
  11. Tang G., Shak S., Paik S. et al. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res. Treat. 2011; 127 (1): 133–42.
  12. Gluck S., de Snoo F., Tian S. Response to neo-adjuvant chemotherapy and outcomes For I-SPY 1 patients stratified by the 70-gene prognosis signature (MammaPrint) and molecular subtyping (BluePrint). Presented at: 34th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 6-10 December 2011.
  13. Kelly C.M., Bernard P.S., Krishnamurthy S. et al. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer. Oncologist. 2012; 17: 492–8.
  14. Fu S.W., Chen L., Man Y.G. miRNA biomarkers in breast cancer detection and management. J. Cancer. 2011; 2: 116–22.
  15. Chin L.J., Slack F.J. A truth serum for cancer microRNAs have major potential as cancer biomarkers. Cell Res. 2008; 18 (10): 983–4.
  16. Guarnieri D.J., Dileone R.J. MicroRNAs: a new class of gene regulators. Ann. Med. 2008; 40 (3): 197–208.
  17. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011; 144 (5): 646–74.
  18. Yu Y.N., Yip G.W., Tan P.H. et al. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle. Int. J. Oncol. 2010; 37 (2): 483–92.
  19. Eliseeva I.A., Kim E.R., Gur`yanov S.G., Ovchinnikov L.P., Lyabin D.N. Y-boks-svyazyvayushhiy belok 1 (YB-1) i ego funkcii. Uspehi biologicheskoy himii. 2011; 51: 65–132. [Eliseeva IA., Kim ER., Guryanov SG., Ovchinnikov LP., Lyabin DN. Y-box-binding protein 1 (YB-1) and its functions. Uspekhi Biologicheskoi Khimii. 2011; 51: 65–132 (in Russian)]
  20. Gens G.P., Fedyaeva V.K., Rebrova O.Yu. Sistematicheskiy obzor original`nyh issledovaniy (s opredeleniem ih metodologicheskogo kachestva) po prognosticheskim svoystvam belka YB-1 v otnoshenii obshhey i bezrecidivnoy vyzhivaemosti bol`nyh rakom molochnoy zhelezy. Rossiyskiy onkologicheskiy zhurnal. 2015; 20 (1): 4–19. [Gens G.P., Fedyaeva V.K., Rebrova O.Yu. Systematic review of prognostic value of the YB-1 protein in breast cancer patients: overall and progression free survival. Russian Journal of Oncology. 2015; 20 (1): 4–19 (in Russian)]
  21. Gens G.P., Moiseeva N.I., Rybalkina E.Yu., Stromskaya T.P., Vayman A.V., Ovchinnikov L.P., Stavrovskaya A.A. Vnutrikletochnaya lokalizaciya belka YB-1 i himioterapiya opuholey molochnoy zhelezy. Rossiyskiy bioterapevticheskiy zhurnal. 2010; 4: 77–84. [Gens G.P., Moiseeva N. I., Rybalkina E.Yu., Stromskaya T.P., Vaiman A.V., Ovchinnikov L.P., Stavrovskaya A.A. Intracellular localization of YB-1 and chemotherapy of breast cancer. Rossiysky Bioterapevtichesky Zhurnal. 2010; 4: 77–84 (in Russian)]
  22. Stavrovskaya A.A., Stromskaya T. P., Rybalkina E. Yu., Moiseeva N. I., Vaiman A. V., Gurjanov S. G., Ovchinnikov L. P., Guens G. P. YB-1 protein and multidrug resistance of tumor cells. Current signal transduction therapy. 2012; 7 (3): 237–46.
  23. Gens G.P., Sulimov A.V., Moiseeva N.I., Ovsiy O.G., Vel`sher L.Z., Rybalkina E.Yu., Selezneva I.I., Savkin I.A., Sulimov V.B. Poisk podhodov k prognozirovaniyu ishodov raka molochnoy zhelezy s pomoshh`yu bayesovskih setey. Onkologiya. Zhurnal im. P.A. Gercena. 2014; 5: 37–46. [Gens G.P., Sulimov A.V., Moiseeva N.I., Ovsij O.G., Vel’sher L.Z., Rybalkina E.Yu., Selezneva I.I., Savkin I.A., Sulimov V.B. Bayesian networks in breast cancer prognosis. Onkologiia. Zhurnal imeni P.A. Gerzena. 2014; 5: 37–46 (in Russian)]